Aug 3, 2015 | Digital Pathology, Instruments & Equipment, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Testing, Management & Operations
Radiology poised to be disrupted as entrepreneurs work to create smaller, cheaper imaging devices that perform as well or better than big, expensive imaging systems
Handheld ultra-sound scanners that are as “cheap as a stethoscope” is the goal of a $100 million development project. Just as the clinical laboratory industry is seeing entrepreneurs pour hundreds of millions of dollars into projects intended to create miniature medical laboratory testing devices, so also is radiology and imaging a target for ambitious entrepreneurs.
The vision of biotechnology entrepreneur Jonathan Rothberg, Ph.D. is to have patients take a trip to their neighborhood drugstore rather than an imaging center the next time they need an ultrasound or MRI.
Rothberg is the driving force behind a $100 million startup called Butterfly Network. He hopes to disrupt the status quo in radiology by creating an ultrasound scanner that “is as cheap as a stethoscope” and would allow physicians or other healthcare professionals to do imaging studies using a device not much larger than a smartphone, MIT Technology Review reports. (more…)
Feb 21, 2014 | Digital Pathology, Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Sales and Marketing, Management & Operations
This price includes all costs except overhead, but without a high volume of customers, Illumina’s $10-million price for the HiSeq X Ten machine may not be a wise investment
Competition continues to be fierce in the race to the $1,000 whole human genome. Most recently, Illumina announced the availability of its latest gene sequencing system, along with the claim that it can deliver a whole human genome at a cost of just $1,000. But, as most pathologists know, the devil is in the details, since not every Illumina customer is likely to achieve that price point.
When Illumina, a San Diego-based technology company, announced its new HiSeq X Ten genetic-sequencing machine in December, 2013, Illumina CEO Jay T. Flatley claimed the company’s system can deliver “full-coverage human genome sequences for less than $1,000,” down from $500 million 10 years ago. The new system is expected to ship in the first quarter of 2014.
(more…)
Dec 18, 2013 | Digital Pathology, Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Management & Operations, Uncategorized
Adoption of digital PCR is slow at this time, but pathologists may want to track how researchers use this technology in the new clinical laboratory assays they use
Molecular pathologists will be interested to learn that there is a new contender in the polymerase chain reaction (PCR) arena. It is digital PCR, and it has specific advantages over traditional real-time PCR methods.
For example, digital PCR can target specific DNA sequences in just one molecule of DNA. This new tool allows researchers to isolate rare genetic mutations too difficult to segregate with real-time PCR, noted a report from Insight Pharma Reports. (more…)
Nov 11, 2013 | Digital Pathology, Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Pathology
The Center brings together scientists from around the city to translate promising research into medical innovations to treat, prevent and manage disease
Gene sequencing is going big time in the Big Apple. Last month the New York Genome Center (NYGC) moved into a state-of-the-art, 170,000-square-foot genome sequencing and biometrics research building. New York City is putting down its marker to claim a leading role in advancing genetic knowledge.
What makes this development notable for the clinical laboratory industry and the anatomic pathology profession is the fact that cities across the nation are investing substantial amounts of capital to create their own genetic and biotech research and development hubs. Their common objective is to bring together all the expertise, financial support, and business acumen needed to create a job-creating critical mass in the fields of biotech and genetic medicine. (more…)
Apr 17, 2013 | Laboratory Hiring & Human Resources, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Sales and Marketing, Management & Operations
Multi-billion-dollar mega-deal positions Thermo Fisher to offer a broader spectrum of gene sequencing systems to clinical laboratories and pathology groups
Earlier this week, Thermo Fisher Scientific, Inc., (NYSE: TMO) of Waltham, Massachusetts, announced a deal that will shake up the market for next-generation gene sequencing and genetic testing. It will acquire Life Technologies Corporation (NASDAQ: LIFE) of Carlsbad, California.
More IVD Industry Consolidation That Affects Clinical Laboratories
It is another example of consolidation involving two companies that sell products to the clinical laboratory and anatomic pathology sectors of the lab medicine marketplace. It is also a multi-billion dollar transaction. Thermo Fisher will pay $13.6 billion for Life Technologies, or $76 per share, according to a Reuters report. This amount represents an 11.7% premium over the $68 price per share of Life Technologies’ stock when trading began Monday morning. (more…)
